🇺🇸 FDA
Patent

US 7256004

Variants of humanized anti-carcinoma monoclonal antibody CC49

granted A61KA61K2039/505A61K38/00

Quick answer

US patent 7256004 (Variants of humanized anti-carcinoma monoclonal antibody CC49) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Aug 09 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Aug 14 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K38/00, A61K49/0002, A61K51/1045